Barclays
MAZE

Barclays’s Maze Therapeutics MAZE Stock Holding History

Barclays’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$708K Buy
23,733
+14,471
+156% +$379K ﹤0.01% 3001
2026
Q1 		$276K Sell
9,262
-30,246
-77% -$1.33M ﹤0.01% 3513
2025
Q4 		$1.64M Buy
39,508
+11,992
+44% +$412K ﹤0.01% 3075
2025
Q3 		$713K Buy
27,516
+12,875
+88% +$217K ﹤0.01% 3586
2025
Q2 		$180K Sell
14,641
-3
-0% -$31 ﹤0.01% 4341
2025
Q1 		$161K Buy
+14,644
New +$176K ﹤0.01% 4162

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Barclays's MAZE Position: Q2 2026 in Review

Barclays increased its Maze Therapeutics (MAZE) stake by 156% in Q2 2026, buying an estimated $379K and bringing the position to 23,733 shares worth $708K. The position accounts for ﹤0.01% of the portfolio, ranked #3001.

Barclays first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.64M in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Barclays held 23,733 shares of Maze Therapeutics worth $708K as of Q2 2026.
  • Barclays bought 14,471 Maze Therapeutics shares in Q2 2026, an estimated $379K.
  • Maze Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3001 holding.
  • Barclays first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Barclays's Maze Therapeutics position peaked at $1.64M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.